Comparison Overview

AUROBINDO PHARMA LTD

VS

MSD

AUROBINDO PHARMA LTD

Galaxy, Floors: 22-24, Plot No.1, Survey No.83/1, Hyderabad Knowledge City, Raidurg Panmaktha, Ranga Reddy District,, Hyderabad, Telangana, IN, 500032
Last Update: 2025-12-09
Between 750 and 799

Aurobindo Pharma Limited (NSE: AUROPHARMA, BSE: 524804, Reuters: ARBN.NS, Bloomberg: ARBP IN) is an integrated global pharmaceutical company headquartered in Hyderabad, India. The Company develops, manufactures, and markets a wide range of generic pharmaceuticals, branded specialty drugs, and active pharmaceutical ingredients (APIs) across more than 150 countries. It is ranked among the top 10 generic companies in eight European nations and holds the distinction of being the largest generic pharmaceutical company in the United States. With over 30 state-of-the-art manufacturing and packaging facilities approved by leading global regulatory authorities including USFDA, UK MHRA, EDQM, Japan PMDA, WHO, Health Canada, South Africa MCC, and Brazil ANVISA, Aurobindo Pharma ensures the highest standards of quality. Its robust portfolio spans eight major therapeutic areas: Central Nervous System (CNS), Antiretroviral (ARV), Cardiovascular (CVS), Antibiotics, Gastroenterology, Anti-diabetics, Oncology, and Dermatology, supported by a strong R&D infrastructure that drives innovation, affordability, and accessibility.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 14,616
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

MSD

90 E Scott Ave, Rahway, New Jersey, US, 07065
Last Update: 2025-12-09
Between 750 and 799

At MSD, known as Merck & Co., Inc., Rahway, NJ, USA in the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than 130 years, we have brought hope to humanity through the development of important medicines and vaccines. We aspire to be the premier research-intensive biopharmaceutical company in the world – and today, we are at the forefront of research to deliver innovative health solutions that advance the prevention and treatment of diseases in people and animals. We foster a diverse and inclusive global workforce and operate responsibly every day to enable a safe, sustainable and healthy future for all people and communities. For more information, visit www.msd.com and connect with us on Facebook, Instagram, Twitter, and YouTube.

NAICS: 3254
NAICS Definition: Pharmaceutical and Medicine Manufacturing
Employees: 35,519
Subsidiaries: 34
12-month incidents
1
Known data breaches
1
Attack type number
1

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
https://images.rankiteo.com/companyimages/msd-global.jpeg
MSD
ISO 27001
ISO 27001 certification not verified
Not verified
SOC2 Type 1
SOC2 Type 1 certification not verified
Not verified
SOC2 Type 2
SOC2 Type 2 certification not verified
Not verified
GDPR
GDPR certification not verified
Not verified
PCI DSS
PCI DSS certification not verified
Not verified
HIPAA
HIPAA certification not verified
Not verified
Compliance Summary
AUROBINDO PHARMA LTD
100%
Compliance Rate
0/4 Standards Verified
MSD
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

No incidents recorded for AUROBINDO PHARMA LTD in 2025.

Incidents vs Pharmaceutical Manufacturing Industry Average (This Year)

MSD has 25.0% more incidents than the average of same-industry companies with at least one recorded incident.

Incident History — AUROBINDO PHARMA LTD (X = Date, Y = Severity)

AUROBINDO PHARMA LTD cyber incidents detection timeline including parent company and subsidiaries

Incident History — MSD (X = Date, Y = Severity)

MSD cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/aurobindopharma.jpeg
AUROBINDO PHARMA LTD
Incidents

No Incident

https://images.rankiteo.com/companyimages/msd-global.jpeg
MSD
Incidents

Date Detected: 9/2025
Type:Breach
Attack Vector: unauthorized access, supply chain compromise
Blog: Blog

FAQ

AUROBINDO PHARMA LTD company demonstrates a stronger AI Cybersecurity Score compared to MSD company, reflecting its advanced cybersecurity posture governance and monitoring frameworks.

MSD company has historically faced a number of disclosed cyber incidents, whereas AUROBINDO PHARMA LTD company has not reported any.

In the current year, MSD company has reported more cyber incidents than AUROBINDO PHARMA LTD company.

Neither MSD company nor AUROBINDO PHARMA LTD company has reported experiencing a ransomware attack publicly.

MSD company has disclosed at least one data breach, while AUROBINDO PHARMA LTD company has not reported such incidents publicly.

Neither MSD company nor AUROBINDO PHARMA LTD company has reported experiencing targeted cyberattacks publicly.

Neither AUROBINDO PHARMA LTD company nor MSD company has reported experiencing or disclosing vulnerabilities publicly.

Neither AUROBINDO PHARMA LTD nor MSD holds any compliance certifications.

Neither company holds any compliance certifications.

MSD company has more subsidiaries worldwide compared to AUROBINDO PHARMA LTD company.

MSD company employs more people globally than AUROBINDO PHARMA LTD company, reflecting its scale as a Pharmaceutical Manufacturing.

Neither AUROBINDO PHARMA LTD nor MSD holds SOC 2 Type 1 certification.

Neither AUROBINDO PHARMA LTD nor MSD holds SOC 2 Type 2 certification.

Neither AUROBINDO PHARMA LTD nor MSD holds ISO 27001 certification.

Neither AUROBINDO PHARMA LTD nor MSD holds PCI DSS certification.

Neither AUROBINDO PHARMA LTD nor MSD holds HIPAA certification.

Neither AUROBINDO PHARMA LTD nor MSD holds GDPR certification.

Latest Global CVEs (Not Company-Specific)

Description

A weakness has been identified in itsourcecode Online Pet Shop Management System 1.0. This vulnerability affects unknown code of the file /pet1/addcnp.php. This manipulation of the argument cnpname causes sql injection. The attack can be initiated remotely. The exploit has been made available to the public and could be exploited.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A security flaw has been discovered in Tenda AX9 22.03.01.46. This affects the function image_check of the component httpd. The manipulation results in use of weak hash. It is possible to launch the attack remotely. A high complexity level is associated with this attack. It is indicated that the exploitability is difficult. The exploit has been released to the public and may be exploited.

Risk Information
cvss2
Base: 2.6
Severity: HIGH
AV:N/AC:H/Au:N/C:N/I:P/A:N
cvss3
Base: 3.7
Severity: HIGH
CVSS:3.1/AV:N/AC:H/PR:N/UI:N/S:U/C:N/I:L/A:N
cvss4
Base: 6.3
Severity: HIGH
CVSS:4.0/AV:N/AC:H/AT:N/PR:N/UI:N/VC:N/VI:L/VA:N/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A weakness has been identified in code-projects Student File Management System 1.0. This issue affects some unknown processing of the file /admin/update_student.php. This manipulation of the argument stud_id causes sql injection. The attack is possible to be carried out remotely. The exploit has been made available to the public and could be exploited.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A security flaw has been discovered in code-projects Student File Management System 1.0. This vulnerability affects unknown code of the file /admin/save_user.php. The manipulation of the argument firstname results in sql injection. The attack can be executed remotely. The exploit has been released to the public and may be exploited.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A vulnerability was identified in code-projects Student File Management System 1.0. This affects an unknown part of the file /admin/update_user.php. The manipulation of the argument user_id leads to sql injection. Remote exploitation of the attack is possible. The exploit is publicly available and might be used.

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X